<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28782275</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>02</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1582-4934</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of cellular and molecular medicine</Title>
          <ISOAbbreviation>J Cell Mol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Emerging role of Hippo signalling pathway in bladder cancer.</ArticleTitle>
        <Pagination>
          <StartPage>4</StartPage>
          <EndPage>15</EndPage>
          <MedlinePgn>4-15</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jcmm.13293</ELocationID>
        <Abstract>
          <AbstractText>Bladder cancer (BC) is one of the most common cancers worldwide with a high progression rate and poor prognosis. The Hippo signalling pathway is a conserved pathway that plays a crucial role in cellular proliferation, differentiation and apoptosis. Furthermore, dysregulation and/or malfunction of the Hippo pathway is common in various human tumours, including BC. In this review, an overview of the Hippo pathway in BC and other cancers is presented. We focus on recent data regarding the Hippo pathway, its network and the regulation of the downstream co-effectors YAP1/TAZ. The core components of the Hippo pathway, which induce BC stemness acquisition, metastasis and chemoresistance, will be emphasized. Additional research on the Hippo pathway will advance our understanding of the mechanism of BC as well as the development and progression of other cancers and may be exploited therapeutically.</AbstractText>
          <CopyrightInformation>© 2017 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley &amp; Sons Ltd and Foundation for Cellular and Molecular Medicine.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xia</LastName>
            <ForeName>Jianling</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Center, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Hospital of the University of Electronic Science and Technology of China, Chengdu, Sichuan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zeng</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Center, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Hospital of the University of Electronic Science and Technology of China, Chengdu, Sichuan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Hua</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xiangjian</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weng</LastName>
            <ForeName>Zhiliang</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Shi</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-5261-2269</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>08</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Cell Mol Med</MedlineTA>
        <NlmUniqueID>101083777</NlmUniqueID>
        <ISSNLinking>1582-1838</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001749" MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Hippo pathway</Keyword>
        <Keyword MajorTopicYN="Y">TAZ</Keyword>
        <Keyword MajorTopicYN="Y">YAP1</Keyword>
        <Keyword MajorTopicYN="Y">bladder cancer</Keyword>
        <Keyword MajorTopicYN="Y">dysregulation</Keyword>
        <Keyword MajorTopicYN="Y">therapeutic target</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>2</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>8</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>8</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28782275</ArticleId>
        <ArticleId IdType="pmc">PMC5742740</ArticleId>
        <ArticleId IdType="doi">10.1111/jcmm.13293</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Miller KD, Siegel RL, Lin CC, et al
Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66: 271–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27253694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Feldman AS, Banyard J, Wu CL, et al
Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res. 2009; 15: 1024–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2728013</ArticleId>
            <ArticleId IdType="pubmed">19188175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
McKellar DP, Nelson H. American college of surgeons commission on cancer rapid quality reporting system: from quality measurement to quality improvement. Bull Am Coll Surg. 2013; 98: 52–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24455822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Heney NM, Ahmed S, Flanagan MJ, et al
Superficial bladder cancer: progression and recurrence. J Urol. 1983; 130: 1083–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6644886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol. 1982; 127: 250–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7062375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sonpavde G, Jones BS, Bellmunt J, et al
Future directions and targeted therapies in bladder cancer. Hematol Oncol Clin North Am. 2015; 29: 361–76, x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25836940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang SP, Wang LH. Disease implication of hyper‐Hippo signalling. Open Biol. 2016; 6: 160119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5090056</ArticleId>
            <ArticleId IdType="pubmed">27805903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kang W, Tong JH, Chan AW, et al
Yes‐associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res. 2011; 17: 2130–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21346147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang Y, Dong Q, Zhang Q, et al
Overexpression of yes‐associated protein contributes to progression and poor prognosis of non‐small‐cell lung cancer. Cancer Sci. 2010; 101: 1279–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20219076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhou D, Conrad C, Xia F, et al
Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 2009; 16: 425–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3023165</ArticleId>
            <ArticleId IdType="pubmed">19878874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang X, George J, Deb S, et al
The Hippo pathway transcriptional co‐activator, YAP, is an ovarian cancer oncogene. Oncogene. 2011; 30: 2810–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21317925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu JY, Li YH, Lin HX, et al
Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer. 2013; 13: 349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3750259</ArticleId>
            <ArticleId IdType="pubmed">23870412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the Roots of Cancer. Cancer Cell. 2016; 29: 783–803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6186419</ArticleId>
            <ArticleId IdType="pubmed">27300434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu JY, Li YH, Lin HX, et al
Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer. 2013; 13: 1–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3750259</ArticleId>
            <ArticleId IdType="pubmed">23870412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li S, Yu Z, Chen SS, et al
The YAP1 oncogene contributes to bladder cancer cell proliferation and migration by regulating the H19 long noncoding RNA. Urol Oncol. 2015; 33: e1–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26163939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zeng Q, Hong W. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell. 2008; 13: 188–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18328423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhao B, Li L, Lei Q, et al
The Hippo‐YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010; 24: 862–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2861185</ArticleId>
            <ArticleId IdType="pubmed">20439427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Justice RW, Zilian O, Woods DF, et al
The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 1995; 9: 534–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7698644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Watson KL. Drosophila warts–tumor suppressor and member of the myotonic dystrophy protein kinase family. BioEssays. 1995; 17: 673–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7661848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tapon N, Harvey KF, Bell DW, et al
salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell. 2002; 110: 467–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12202036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wu S, Huang J, Dong J, et al
hippo encodes a Ste‐20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell. 2003; 114: 445–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12941273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hariharan IK, Bilder D. Regulation of imaginal disc growth by tumor‐suppressor genes in Drosophila. Annu Rev Genet. 2006; 40: 335–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16872256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bergstralh DT, St Johnston D. Epithelial cell polarity: what flies can teach us about cancer. Essays Biochem. 2012; 53: 129–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22928513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xu T, Wang W, Zhang S, et al
Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development. 1995; 121: 1053–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7743921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pantalacci S, Tapon N, Leopold P. The Salvador partner Hippo promotes apoptosis and cell‐cycle exit in Drosophila. Nat Cell Biol. 2003; 5: 921–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14502295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Harvey KF, Pfleger CM, Hariharan IK. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 2003; 114: 457–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12941274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yu F‐X, Zhao B, Panupinthu N, et al
Regulation of the Hippo‐YAP Pathway by G‐Protein‐Coupled receptor signaling. Cell. 2012; 150: 780–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3433174</ArticleId>
            <ArticleId IdType="pubmed">22863277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gandhirajan RK, Jain M, Walla B, et al
Cysteine S‐Glutathionylation promotes stability and activation of the Hippo downstream effector transcriptional co‐activator with PDZ‐binding motif (TAZ). J Biol Chem. 2016; 291: 11596–607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4882430</ArticleId>
            <ArticleId IdType="pubmed">27048650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Del Re Dominic P, Matsuda T, Zhai P, et al
Mst1 promotes cardiac myocyte apoptosis through phosphorylation and inhibition of Bcl‐xL. Mol Cell. 2014; 54: 639–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4074544</ArticleId>
            <ArticleId IdType="pubmed">24813943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
O'Neill E, Rushworth L, Baccarini M, et al
Role of the kinase MST2 in suppression of apoptosis by the proto‐oncogene product Raf‐1. Science. 2004; 306: 2267–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15618521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Romano D, Matallanas D, Weitsman G, et al
Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf‐1, and Akt. Cancer Res. 2010; 70: 1195–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2880716</ArticleId>
            <ArticleId IdType="pubmed">20086174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hoa L, Kulaberoglu Y, Gundogdu R, et al
The characterisation of LATS2 kinase regulation in Hippo‐YAP signalling. Cell Signal. 2016; 28: 488–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26898830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ni L, Zheng Y, Hara M, et al
Structural basis for Mob1‐dependent activation of the core Mst‐Lats kinase cascade in Hippo signaling. Genes Dev. 2015; 29: 1416–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4511216</ArticleId>
            <ArticleId IdType="pubmed">26108669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Guo C, Zhang X, Pfeifer GP. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20‐like kinases MST1 and MST2. J Biol Chem. 2011; 286: 6253–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3057778</ArticleId>
            <ArticleId IdType="pubmed">21199877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ribeiro PS, Josué F, Wepf A, et al
Combined functional genomic and proteomic approaches identify a PP2A complex as a negative regulator of Hippo signaling. Mol Cell. 2010; 39: 521–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20797625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Varelas X, Miller BW, Sopko R, et al
The Hippo pathway regulates Wnt/beta‐catenin signaling. Dev Cell. 2010; 18: 579–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20412773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang H, Liu CY, Zha ZY, et al
TEAD transcription factors mediate the function of TAZ in cell growth and epithelial‐mesenchymal transition. J Biol Chem. 2009; 284: 13355–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2679435</ArticleId>
            <ArticleId IdType="pubmed">19324877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhao B, Ye X, Yu J, et al
TEAD mediates YAP‐dependent gene induction and growth control. Genes Dev. 2008; 22: 1962–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2492741</ArticleId>
            <ArticleId IdType="pubmed">18579750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lai D, Ho KC, Hao Y, et al
Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Can Res. 2011; 71: 2728–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21349946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Meng Z, Moroishi T, Guan KL. Mechanisms of Hippo pathway regulation. Genes Dev. 2016; 30: 1–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4701972</ArticleId>
            <ArticleId IdType="pubmed">26728553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sansores‐Garcia L, Atkins M, Moya IM, et al
Mask is required for the activity of the Hippo pathway effector Yki/YAP. Curr Biol. 2013; 23: 229–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4089957</ArticleId>
            <ArticleId IdType="pubmed">23333314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Enderle L, McNeill H. Hippo gains weight: added insights and complexity to pathway control. Sci Signal. 2013; 6: re7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24106343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Smith RK, Carroll PM, Allard JD, et al
MASK, a large ankyrin repeat and KH domain‐containing protein involved in Drosophila receptor tyrosine kinase signaling. Development. 2002; 129: 71–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11782402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Poulin F, Brueschke A, Sonenberg N. Gene fusion and overlapping reading frames in the mammalian genes for 4E‐BP3 and MASK. J Biol Chem. 2003; 278: 52290–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14557257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Elbediwy A, Vincentmistiaen ZI, Thompson BJ. YAP and TAZ in epithelial stem cells: a sensor for cell polarity, mechanical forces and tissue damage. BioEssays. 2016; 38: 644–653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5031209</ArticleId>
            <ArticleId IdType="pubmed">27173018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lecuit T, Yap AS. E‐cadherin junctions as active mechanical integrators in tissue dynamics. Nat Cell Biol. 2015; 17: 533–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25925582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fernández BG, Gaspar P, Bráspereira C, et al
Actin‐Capping Protein and the Hippo pathway regulate F‐actin and tissue growth in Drosophila. Development. 2011; 138: 2337–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21525075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dupont S, Morsut L, Aragona M, et al
Role of YAP/TAZ in mechanotransduction. Nature. 2011; 474: 179–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21654799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pathak MM, Nourse JL, Tran T, et al
Stretch‐activated ion channel Piezo1 directs lineage choice in human neural stem cells. Proc Natl Acad Sci USA. 2014; 111: 16148–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4234578</ArticleId>
            <ArticleId IdType="pubmed">25349416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dong J, Feldmann G, Huang J, et al
Elucidation of a universal size‐control mechanism in Drosophila and mammals. Cell. 2007; 130: 1120–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2666353</ArticleId>
            <ArticleId IdType="pubmed">17889654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
DeRan M, Yang J, Shen CH, et al
Energy stress regulates hippo‐YAP signaling involving AMPK‐mediated regulation of angiomotin‐like 1 protein. Cell Rep. 2014; 9: 495–503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4223634</ArticleId>
            <ArticleId IdType="pubmed">25373897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mo JS, Meng Z, Kim YC, et al
Cellular energy stress induces AMPK‐mediated regulation of YAP and the Hippo pathway. Nat Cell Biol. 2015; 17: 500–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4380774</ArticleId>
            <ArticleId IdType="pubmed">25751140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ma B, Chen Y, Chen L, et al
Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase. Nat Cell Biol. 2015; 17: 95–103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25438054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Miller E, Yang J, DeRan M, et al
Identification of serum‐derived sphingosine‐1‐phosphate as a small molecule regulator of YAP. Chem Biol. 2012; 19: 955–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22884261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mo JS, Yu FX, Gong R, et al
Regulation of the Hippo‐YAP pathway by protease‐activated receptors (PARs). Genes Dev. 2012; 26: 2138–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3465735</ArticleId>
            <ArticleId IdType="pubmed">22972936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gong R, Hong AW, Plouffe SW, et al
Opposing roles of conventional and novel PKC isoforms in Hippo‐YAP pathway regulation. Cell Res. 2015; 25: 985–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4528059</ArticleId>
            <ArticleId IdType="pubmed">26206313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhou X, Wang S, Wang Z, et al
Estrogen regulates Hippo signaling via GPER in breast cancer. J Clin Invest. 2015; 125: 2123–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4463207</ArticleId>
            <ArticleId IdType="pubmed">25893606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yu FX, Zhang Y, Park HW, et al
Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Genes Dev. 2013; 27: 1223–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3690396</ArticleId>
            <ArticleId IdType="pubmed">23752589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Desprez PY, Sumida T, Coppé JP. Helix‐loop‐helix proteins in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia. 2003; 8: 225–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14635797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kee BL. E and ID proteins branch out. Nat Rev Immunol. 2009; 9: 175–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19240756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang LH, Baker NE. Salvador‐Warts‐Hippo Pathway in a developmental checkpoint monitoring Helix‐Loop‐Helix Proteins. Dev Cell. 2015; 32: 191–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4308471</ArticleId>
            <ArticleId IdType="pubmed">25579975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Peng HW, Slattery M, Mann RS. Transcription factor choice in the Hippo signaling pathway: homothorax and yorkie regulation of the microRNA bantam in the progenitor domain of the Drosophila eye imaginal disc. Genes Dev. 2009; 23: 2307–19. 66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2758742</ArticleId>
            <ArticleId IdType="pubmed">19762509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alarcón C, Zaromytidou AI, Xi Q, et al
Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF‐beta pathways. Cell. 2009; 139: 757–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2818353</ArticleId>
            <ArticleId IdType="pubmed">19914168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hong JH, Hwang ES, Mcmanus MT, et al
TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science. 2005; 309: 1074–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16099986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang L, Ren F, Zhang Q, et al
The TEAD/TEF Family of Transcription Factor Scalloped Mediates Hippo Signaling in Organ Size Control. Dev Cell. 2008; 14: 377–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2292673</ArticleId>
            <ArticleId IdType="pubmed">18258485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tao W, Zhang S, Turenchalk GS, et al
Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nat Genet. 1999; 21: 177–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9988268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang S, Zhang L, Purohit V, et al
Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation‐dependent manner through LPAR3. Oncotarget. 2015; 6: 36019–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4742158</ArticleId>
            <ArticleId IdType="pubmed">26440309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tschaharganeh DF, Chen X, Latzko P, et al
Yes‐Associated Protein Up‐regulates Jagged‐1 and Activates the NOTCH Pathway in Human Hepatocellular Carcinoma. Gastroenterology. 2013; 144: 1530–U368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3665638</ArticleId>
            <ArticleId IdType="pubmed">23419361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fujii M, Toyoda T, Nakanishi H, et al
TGF‐β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med. 2012; 209: 479–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3302232</ArticleId>
            <ArticleId IdType="pubmed">22329991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim M, Jho E‐H. Cross‐talk between Wnt/beta‐catenin and Hippo signaling pathways: a brief review. Bmb Rep. 2014; 47: 540–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4261510</ArticleId>
            <ArticleId IdType="pubmed">25154721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim S, Jho E‐H. Merlin, a regulator of Hippo signaling, regulates Wnt/beta‐catenin signaling. Bmb Rep. 2016; 49: 357–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5032002</ArticleId>
            <ArticleId IdType="pubmed">27345717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Clevers H. Wnt/beta‐catenin signaling in development and disease. Cell. 2006; 127: 469–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17081971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Imajo M, Miyatake K, Iimura A, et al
A molecular mechanism that links Hippo signalling to the inhibition of Wnt/beta‐catenin signalling. EMBO J. 2012; 31: 1109–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3297994</ArticleId>
            <ArticleId IdType="pubmed">22234184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Konsavage WM, Kyler SL, Rennoll SA, et al
Wnt/β‐Catenin signaling regulates yes‐associated protein (YAP) Gene expression in colorectal carcinoma cells. J Biol Chem. 2012; 287: 11730–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3320921</ArticleId>
            <ArticleId IdType="pubmed">22337891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rosenbluh J, Nijhawan D, Cox AG, et al
beta‐Catenin‐driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012; 151: 1457–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3530160</ArticleId>
            <ArticleId IdType="pubmed">23245941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Makita R, Uchijima Y, Nishiyama K, et al
Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. Am J Physiol. 2008; 294: F542–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18172001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Heallen T, Zhang M, Wang J, et al
Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science. 2011; 332: 458–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3133743</ArticleId>
            <ArticleId IdType="pubmed">21512031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hay BA, Guo M. Coupling cell growth, proliferation, and death. Hippo weighs in. Dev Cell. 2003; 5: 361–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12967554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moroishi T, Hayashi T, Pan WW, et al
The Hippo Pathway Kinases LATS1/2 suppress cancer immunity. Cell. 2016; 167: 1525–1539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5512418</ArticleId>
            <ArticleId IdType="pubmed">27912060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Karamitopoulou E, Zlobec I, Patsouris E, et al
Loss of E‐cadherin independently predicts the lymph node status in colorectal cancer. Pathology. 2011; 43: 133–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21233674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liang K, Zhou G, Zhang Q, et al
Expression of hippo pathway in colorectal cancer. Saudi J Gastroenterol. 2014; 20: 188–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4067916</ArticleId>
            <ArticleId IdType="pubmed">24976283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lin X, Cai F, Li X, et al
Prognostic significance of mammalian sterile 20‐like kinase 1 in breast cancer. Tumor Biol. 2013; 34: 3239–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23737290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhou G‐X, Li X‐Y, Zhang Q, et al
Effects of the hippo signaling pathway in human gastric cancer. Asian Pac J Cancer Prev. 2013; 14: 199–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24175801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yagi H, Asanoma K, Ohgami T, et al
GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer. Oncogene. 2016; 35: 4471–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26804165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Machado‐Neto JA, Lazarini M, Favaro P, et al
ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. Exp Cell Res. 2014; 324: 137–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24726915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dhyani A, Machado‐Neto JA, Favaro P, et al
ANKHD1 represses p21 (WAF1/CIP1) promoter and promotes multiple myeloma cell growth. Eur J Cancer. 2015; 51: 252–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25483783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Traina F, Favaro PM, Medina Sde S, et al
ANKHD1, ankyrin repeat and KH domain containing 1, is overexpressed in acute leukemias and is associated with SHP2 in K562 cells. Biochem Biophys Acta. 2006; 1762: 828–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16956752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dong L, Lin F, Wu W, et al
Transcriptional cofactor Mask2 is required for YAP‐induced cell growth and migration in bladder cancer cell. J Cancer. 2016; 7: 2132–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5118678</ArticleId>
            <ArticleId IdType="pubmed">27877230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ge L, Smail M, Meng W, et al
Yes‐associated protein expression in head and neck squamous cell carcinoma nodal metastasis. PLoS ONE. 2011; 6: e27529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3212574</ArticleId>
            <ArticleId IdType="pubmed">22096589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pei T, Li Y, Wang J, et al
YAP is a critical oncogene in human cholangiocarcinoma. Oncotarget. 2015; 6: 17206–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4627302</ArticleId>
            <ArticleId IdType="pubmed">26015398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Su L, Ma W, Yuan J, et al
Expression of Yes‐associated protein in non‐small cell lung cancer and its relationship with clinical pathological factors. Chin Med J. 2012; 125: 4003–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23158133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yoo JH, Shi DS, Grossmann AH, et al
ARF6 Is an actionable node that orchestrates oncogenic GNAQ Signaling in Uveal melanoma. Cancer Cell. 2016; 29: 889–904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5027844</ArticleId>
            <ArticleId IdType="pubmed">27265506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang C, Gu C, Jeong KJ, et al
YAP/TAZ‐Mediated upregulation of GAB2 leads to increased sensitivity to growth factor‐induced activation of the PI3K pathway. Cancer Res. 2017; 77: 1637–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6026015</ArticleId>
            <ArticleId IdType="pubmed">28202507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cai WY, Lin LY, Hao H, et al
Yes‐associated protein/TEA domain family member and hepatocyte nuclear factor 4‐Alpha (HNF4 alpha) repress reciprocally to regulate hepatocarcinogenesis in rats and mice. Hepatology. 2017; 65: 1206–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27809333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Murakami S, Shahbazian D, Surana R, et al
Yes‐associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene. 2017; 36: 1232–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5322249</ArticleId>
            <ArticleId IdType="pubmed">27546622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Guo Y, Pan Q, Zhang J, et al
Functional and clinical evidence that TAZ is a candidate oncogene in hepatocellular carcinoma. J Cell Biochem. 2015; 116: 2465–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25650113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li Z, Wang Y, Zhu Y, et al
The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer. Mol Oncol. 2015; 9: 1091–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5528756</ArticleId>
            <ArticleId IdType="pubmed">25704916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wei Z, Wang Y, Li Z, et al
Overexpression of Hippo pathway effector TAZ in tongue squamous cell carcinoma: correlation with clinicopathological features and patients’ prognosis. J Oral Pathol Med. 2013; 42: 747–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23551691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xie M, Zhang L, He C‐S, et al
Prognostic significance of TAZ expression in resected non‐small cell lung cancer. J Thorac Oncol. 2012; 7: 799–807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22481233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zeng C, Huang L, Zheng Y, et al
[Expression of transcriptional coactivator with PDZ‐binding motif (TAZ) in colon cancer tissues and its clinical significance]. Zhonghua wei chang wai ke za zhi. 2015; 18: 1154–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26616814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang Y, Xue C, Cui H, et al
High expression of TAZ indicates a poor prognosis in retinoblastoma. Diagn Pathol. 2015; 10: 187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4605227</ArticleId>
            <ArticleId IdType="pubmed">26464030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhan M, Ikeda JI, Wada N, et al
Prognostic significance of a component of the Hippo pathway, TAZ, in human uterine endometrioid adenocarcinoma. Oncol Lett. 2016; 11: 3611–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4887927</ArticleId>
            <ArticleId IdType="pubmed">27284362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen G, Xie J, Huang P, et al
Overexpression of TAZ promotes cell proliferation, migration and epithelial‐mesenchymal transition in ovarian cancer. Oncol Lett. 2016; 12: 1821–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4997911</ArticleId>
            <ArticleId IdType="pubmed">27588129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ma J, Huang K, Ma Y, et al
The TAZ‐miR‐224‐SMAD4 axis promotes tumorigenesis in osteosarcoma. Cell Death Dis. 2017; 8: e2539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5386375</ArticleId>
            <ArticleId IdType="pubmed">28055015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Qiu X, Jiao J, Li Y, et al
Overexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ. Oncotarget. 2016; 7: 85987–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5349891</ArticleId>
            <ArticleId IdType="pubmed">27852064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Han S‐X, Bai E, Jin G‐H, et al
Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res. 2014; 2014: 261365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4016924</ArticleId>
            <ArticleId IdType="pubmed">24860833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shen S, Guo X, Yan H, et al
A miR‐130a‐YAP positive feedback loop promotes organ size and tumorigenesis. Cell Res. 2015; 25: 997–1012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4559818</ArticleId>
            <ArticleId IdType="pubmed">26272168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tao J, Calvisi DF, Ranganathan S, et al
Activation of β‐catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology. 2014; 147: 690–701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4143445</ArticleId>
            <ArticleId IdType="pubmed">24837480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xu M, Chan S, Liu A, et al
AXL receptor kinase is a mediator of YAP‐dependent oncogenic functions in hepatocellular carcinoma. Oncogene. 2011; 30: 1229–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3330262</ArticleId>
            <ArticleId IdType="pubmed">21076472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cordenonsi M, Zanconato F, Azzolin L, et al
The Hippo transducer TAZ confers cancer stem cell‐related traits on breast cancer cells. Cell. 2011; 147: 759–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22078877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Di Agostino S, Sorrentino G, Ingallina E, et al
YAP enhances the pro‐proliferative transcriptional activity of mutant p53 proteins. EMBO Rep. 2016; 17(2): 188–201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5290815</ArticleId>
            <ArticleId IdType="pubmed">26691213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zanconato F, Piccolo S. Eradicating tumor drug resistance at its YAP‐biomechanical roots. EMBO J. 2016; 35(5): 459–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4772852</ArticleId>
            <ArticleId IdType="pubmed">26711176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fernandez LA, Northcott PA, Dalton J, et al
YAP1 is amplified and up‐regulated in hedgehog‐associated medulloblastomas and mediates Sonic hedgehog‐driven neural precursor proliferation. Genes Dev. 2009; 23: 2729–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2788333</ArticleId>
            <ArticleId IdType="pubmed">19952108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen D, Sun Y, Wei Y, et al
LIFR is a breast cancer metastasis suppressor upstream of the Hippo‐YAP pathway and a prognostic marker. Nat Med. 2012; 18: 1511–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3684419</ArticleId>
            <ArticleId IdType="pubmed">23001183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cheng H, Zhang Z, Rodriguez‐Barrueco R, et al
Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells. Oncotarget. 2016; 7(20): 28976–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5045371</ArticleId>
            <ArticleId IdType="pubmed">26716514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Noguchi S, Saito A, Horie M, et al
An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non‐Small Cell Lung Cancer. Clin Cancer Res. 2014; 20: 4660–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24951773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bora‐Singhal N, Nguyen J, Schaal C, et al
YAP1 Regulates OCT4 Activity and SOX2 Expression to Facilitate Self‐Renewal and Vascular Mimicry of Stem‐Like Cells. Stem Cells. 2015; 33: 1705–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4441573</ArticleId>
            <ArticleId IdType="pubmed">25754111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lau AN, Curtis SJ, Fillmore CM, et al
Tumor‐propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J. 2014; 33: 468–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3989628</ArticleId>
            <ArticleId IdType="pubmed">24497554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mohseni M, Sun J, Lau A, et al
A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway. Nat Cell Biol. 2014; 16: 108–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4159053</ArticleId>
            <ArticleId IdType="pubmed">24362629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gayyed MF. The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway. Journal of Gastrointestinal Cancer. 2006; 37: 103–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18175224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vitolo MI, Al E. The RUNX2 transcription factor cooperates with the YES‐associated protein, YAP65, to promote cell transformation. Cancer Biol Ther. 2007; 6: 856–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17438369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yue G, Sun X, Gimenez‐Capitan A, et al
TAZ is highly expressed in gastric signet ring cell carcinoma. Biomed Res Int. 2014; 2014: 393064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3953576</ArticleId>
            <ArticleId IdType="pubmed">24707483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jiao S, Wang H, Shi Z, et al
A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014; 25: 166–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24525233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee K, Sook LS, Kim S, et al
Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients. Clin Cancer Res. 2014; 21: 357–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4513664</ArticleId>
            <ArticleId IdType="pubmed">25388162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim DH, Kim SH, Lee OJ, et al
Differential expression of Yes‐associated protein and phosphorylated Yes‐associated protein is correlated with expression of Ki‐67 and phospho‐ERK in colorectal adenocarcinoma. Histol Histopathol. 2013; 28: 1483–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23673988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Plouffe SW, Hong AW, Guan KL. Disease implications of the Hippo/YAP pathway. Trends Mol Med. 2015; 21: 212–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4385444</ArticleId>
            <ArticleId IdType="pubmed">25702974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chia I, Grote D, Marcotte M, et al
Nephric duct insertion is a crucial step in urinary tract maturation that is regulated by a Gata3‐Raldh2‐Ret molecular network in mice. Development. 2011; 138: 2089–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3082308</ArticleId>
            <ArticleId IdType="pubmed">21521737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Reginensi A, Hoshi M, Boualia SK, et al
Yap and Taz are required for Ret‐dependent urinary tract morphogenesis. Development. 2015; 142: 2696–703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4529030</ArticleId>
            <ArticleId IdType="pubmed">26243870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Saadeldin MK, Shawer H, Mostafa A, et al
New genetic variants of LATS1 detected in urinary bladder and colon cancer. Front Genet. 2015; 5: 425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4292772</ArticleId>
            <ArticleId IdType="pubmed">25628642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Min B, Kim MK, Zhang JW, et al
Identification of RUNX3 as a component of the MST/Hpo signaling pathway. J Cell Physiol. 2012; 227: 839–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3632350</ArticleId>
            <ArticleId IdType="pubmed">21678419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Qiao Y, Lin SJ, Chen Y, et al
RUNX3 is a novel negative regulator of oncogenic TEAD‐YAP complex in gastric cancer. Oncogene. 2015; 35: 2664–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26364597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li XJ, Park ES, Park MH, et al
3,3’‐Diindolylmethane suppresses the growth of gastric cancer cells via activation of the Hippo signaling pathway. Oncol Rep. 2013; 30: 2419–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24008339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Latz S, Umbach T, Goltz D, et al
Cytoplasmatic and Nuclear YAP1 and pYAP1 Staining in Urothelial Bladder Cancer. Urol Int. 2016; 96: 39–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26287745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013; 13: 246–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23467301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gao Y, Shi Q, Xu S, et al
Curcumin promotes KLF5 proteasome degradation through downregulating YAP/TAZ in bladder cancer cells. Int J Mol Sci. 2014; 15: 15173–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4200832</ArticleId>
            <ArticleId IdType="pubmed">25170806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Panciera T, Azzolin L, Fujimura A, et al
Induction of Expandable Tissue‐Specific Stem/Progenitor Cells through Transient Expression of YAP/TAZ. Cell Stem Cell. 2016; 19: 725–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5145813</ArticleId>
            <ArticleId IdType="pubmed">27641305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bartucci M, Dattilo R, Moriconi C, et al
TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene. 2015; 34: 681–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24531710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baia GS, Caballero OL, Orr BA, et al
Yes‐associated protein 1 is activated and functions as an oncogene in meningiomas. Mol Cancer Res. 2012; 10: 904–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4703097</ArticleId>
            <ArticleId IdType="pubmed">22618028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mao B, Hu F, Cheng J, et al
SIRT1 regulates YAP2‐mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene. 2014; 33: 1468–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23542177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ciamporcero E, Shen H, Ramakrishnan S, et al
YAP activation protects urothelial cell carcinoma from treatment‐induced DNA damage. Oncogene. 2016; 35: 1541–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4695331</ArticleId>
            <ArticleId IdType="pubmed">26119935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Esrig D, Elmajian D, Groshen S, et al
Accumulation of nuclear P53 and tumor progression in bladder‐cancer. N Engl J Med. 1994; 331: 1259–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7935683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jeong KC, Kim KT, Seo HH, et al
Intravesical instillation of c‐MYC inhibitor KSI‐3716 suppresses orthotopic bladder tumor growth. J Urol. 2014; 191: 510–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23872029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hoshino M, Qi ML, Yoshimura N, et al
Transcriptional repression induces a slowly progressive atypical neuronal death associated with changes of YAP isoforms and p73. J Cell Biol. 2006; 172: 589–604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2063678</ArticleId>
            <ArticleId IdType="pubmed">16461361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Levy D, Adamovich Y, Reuven N, et al
The Yes‐associated protein 1 stabilizes p73 by preventing Itch‐mediated ubiquitination of p73. Cell Death Differ. 2007; 14: 743–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17110958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xiao W, Wang J, Ou C, et al
Mutual interaction between YAP and c‐Myc is critical for carcinogenesis in liver cancer. Biochem Biophys Res Commun. 2013; 439: 167–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23994632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Singh R, Ansari JA, Maurya N, et al
Epithelial‐to‐mesenchymal transition and its correlation with clinicopathologic features in patients with urothelial carcinoma of the bladder. Clin Genitourin Cancer. 2017; 15: e187–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27601277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shao DD, Xue W, Krall EB, et al
KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014; 158: 171–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4110062</ArticleId>
            <ArticleId IdType="pubmed">24954536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Luo M, Li ZW, Wang W, et al
Long non‐coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E‐cadherin expression. Cancer Lett. 2013; 333: 213–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23354591</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
